Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns
Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns
复制标题
DOI：
10.1099/0022-1317-82-5-1001
复制
发表时间：
2001-05-01
影响因子：
3.8
通讯作者：
Dény, P
中科院分区：
文献类型：
--
作者：
Morice, Y;Roulot, D;Dény, P
丙型肝炎病毒（HCV）具有高度的遗传变异性，可分为6个分支。在巴黎东北部的塞纳-圣但尼区，通常感染非洲或中东人群的HCV-4的患病率是整个法国大陆记录的两倍（102对4.5%）。虽然HCV-4的致病性仍然未知，但HCV-4对治疗的抗性似乎与HCV-1相似。为了描述巴黎HCV-4的流行病学特征，从38名HCV-4感染患者中获得非结构性5 B基因（332 bp）的序列。广泛的系统发育分析表明，7个不同的HCV-4亚型。此外，系统发育树拓扑结构明确区分两种流行病学概况。第一个概况（52.6%的患者）反映了两个不同的HCV-4亚型主要发生在静脉吸毒者（65%的患者）中的郊区内出现。第二个图谱显示了6个亚支[HCV-4a、-4f、-4h、-4k、-4a（B）和一个新序列]，并解释了来自非洲（埃及和撒哈拉以南国家）的患者，这些患者具有未知的风险因素（77.8%的患者），并且在这些患者中没有明显的近期HCV-4扩散。这项研究表明，在法国吸毒者中HCV-4的高度多样性和HCV-4a和-4d亚支的延伸。
Hepatitis C virus (HCV) has been classified into six clades as a result of high genetic variability. In the Seine-Saint-Denis district of north-east Paris, the prevalence of HCV-4, which usually infects populations from Africa or the Middle East, is twice as high as that recorded for the whole of continental France(102 versus 4.5%). Although the pathogenicity of HCV-4 remains unknown, resistance of HCV-4 to therapy appears to be similar to that observed for HCV-1. In order to characterize the epidemiology of HCV-4 in Paris, sequences of the non-structural 5B gene (332 bp) were obtained from 38 HCV-4-infected patients. Extensive phylogenetic analyses indicated seven different HCV-4 subtypes. Moreover, phylogenetic tree topologies clearly distinguished two epidemiological profiles. The first profile (52.6% of patients) reflects the intra-suburban emergence of two distinct HCV-4 subclades occurring mainly among intravenous drug users (65% of patients). The second profile shows six subclades [HCV-4a, -4f, -4h, -4k, -4a(B) and a new sequence] and accounts for patients from Africa (Egypt and sub-Saharan countries) who have unknown risk factors (77.8% of patients) and in whom no recent diffusion of HCV-4 is evident. This study indicates the high diversity of HCV-4 and the extension of HCV-4a and -4d subclades among drug users in France.